CUE - Company ID 0001645460
The table below shows Cue Biopharma, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $27.47M | $9.29M | $5.49M | $1.25M | $14.94M | $3.15M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $37.74M | $36.30M | $40.80M | $38.58M | $41.35M | $33.55M |
| SG&A |
Cue Biopharma, Inc. reported annual revenue of $27.47M for fiscal year 2025. That is up 195.7% from $9.29M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $1.14M (FY 2018) to $27.47M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $16.24M |
| $14.59M |
| $16.68M |
| $16.17M |
| $17.31M |
| $14.65M |
| Operating income | -$26.55M | -$41.50M | -$52.15M | -$53.23M | -$43.71M | -$45.04M |
| Income tax | $500.00K | $0.00 | - | $0.00 | $495.00K | $206.25K |
| Net income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | -$44.16M | -$44.78M |
| EPS (diluted) | -$0.28 | -$0.72 | -$1.11 | -$1.49 | -$1.41 | - |